FDA revises Lilly's COVID-19 antibody combo EUA for use after exposure to virus
Reuters
Published Sep 16, 2021 03:38PM ET
Updated Sep 16, 2021 04:00PM ET
(Reuters) -The U.S. Food and Drug Administration said on Thursday it has revised its emergency use authorization for Eli Lilly (NYSE:LLY)'s COVID-19 antibody cocktail to include for use in patients who have been exposed to the virus and are at high risk for progression to severe disease.
The cocktail, bamlanivimab and etesevimab, was authorized in February for use in people 12 years and above with mild-to-moderate infection and are at high risk for progression to severe COVID-19.
However, the FDA said on Thursday the cocktail is not a substitute for vaccination against COVID-19. (https://
The FDA said that bamlanivimab and etesevimab, which are administered together, could be also used as post-exposure prevention for patients who are not fully vaccinated or who are not expected to mount an adequate immune response to complete vaccination or have been exposed to an individual infected with the virus.
The revision comes a day after the U.S. government bought 388,000 additional doses of Lilly's COVID-19 antibody therapy.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.